Clinical trial NCT06565780: Evaluation of the Performance and Safety of the Aktiia Spot-check Optical Blood Pressure Monitoring Device At Wrist Against Double Auscultation
Official title: Evaluation of the Performance and Safety of the Aktiia Spot-check Optical Blood Pressure Monitoring (OBPM) Device At Wrist Against Double Auscultation: a Multicentric Prospective Clinical Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hypertension
Keywords: hypertension
blood pressure
Lead sponsor: Aktiia SA
Sponsor class: INDUSTRY
First posted: 2024-08-22
Enrollment: 140
Sex: ALL
Minimum age (years): 22
Maximum age (years): 59
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: This study, with N = 85 participants minimum over 3 visits spread over 23 hours, has been designed to assess the accuracy and precision of the Blood Pressure and pulse rate values as generated by Aktiia.product-G0 for up to 23 hours after initialization in a cohort of subjects representative of the US population.

For the study, subjects will be asked to stay seated while measurements are taken at different timepoints.


Eligibility criteria: Inclusion Criteria:

1. Participants must be able to provide an informed consent to participate.
2. Participant must be willing and able to comply with all of the study procedures and return for a day 2 visit.
3. Participants must be 22 to 59 years of age.
4. Participant or witness must be able to read or write in English.

Exclusion Criteria:

1. Participants with compromised circulation, injury, or physical malformation of the equipment test sites or other sensor sites which would limit the ability to test sites needed for the study. (Note: Certain malformations may still allow participants to participate if the condition is noted and would not affect the sites utilized.)
2. Female participants who are known to be pregnant or who are trying to get pregnant confirmed by a day 1 positive urine pregnancy test unless the study participant is known to be not of child-bearing potential.
3. Participants with known clotting disorders or currently taking a prescription blood thinner.
4. Other known health conditions that will prevent safe participation in the study upon disclosure in Health Assessment Short Form or verbally.
5. Participants suffering from sustained cardiac arrhythmias that can lead to weak or unstable pressure pulses including tachycardia (heart rate at rest \> 120bpm) and atrial fibrillation.
6. Participants suffering from pathologies that systematically reduce peripheral perfusion including Raynaud's disease, diabetes, renal dysfunctions (eGFR \< 60mL / min / 1.73 m2), hyper- / hypothyroidism, pheochromocytoma or arteriovenous fistula.
7. A wrist circumference below 14 cm or above 23 cm.
8. An upper arm circumference \< 22cm or \> 42cm.
9. Any subject that, in the opinion of the investigator, does not exhibit any phenotype relevant to the objectives of this study.
10. Any condition or circumstance that, in the opinion of the investigator, may preclude study completion, interfere with accurate data collection, bias the results, by instance a subject presenting a lateral Blood Pressure difference at screening of more than 15 mmHg for the systolic and/or more than 10 mmHg for the diastolic.

Primary outcomes:
measure: Blood pressure mean value of differences
timeFrame: 23 hours
measure: Blood pressure standard deviation of differences
timeFrame: 23 hours
Secondary outcomes:
measure: Heart rate root-mean-square error
timeFrame: 23 hours
Other outcomes:
Locations:
city: Broomfield
country: United States
facility: Parameters Research Laboratory
state: Colorado
Study officials:
References: